Roche also participated in the Agilent Technologies-led round, which will fund the launch of Purigen's isotachophoresis-based DNA and RNA sample preparation platform.
Diagnostics services provider Agilent Technologies has led a $26.4m series B round for US-based laboratory technology developer Purigen Biosystems.
Roche Venture Fund, the corporate venturing unit of pharmaceutical firm Roche, also took part in the round, as did investment firm Cota Capital and venture capital firm 5AM Ventures.
Purigen is developing a platform that allows users to purify DNA and RNA from biological samples, including mammalian cells, fresh or formalin-fixed paraffin-embedded tissues, liquid biopsies, plasma, blood and buccal smears, using…
